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Value of the 99mTc-methylene diphosphonate bone scan in renal
osteodystrophy. The value of radionuclide bone scanning in the diagno-
sis of renal osteodystrophy is still debated. In order to re-examine this
issue, 25 uremic patients treated by intermittent hemodialysis under-
went 99m-Technetium Methylene Diphosphonate (99mTc-MDP) bone
scan. They were subdivided into three groups according to quantitative
bone histology. Group I (N 8) had pure dialysis osteomalacia, group
2 (N = 7) mixed lesions, and group 3 (N = 10) pure osteitis fibrosa. The
scintigraphic studies were interpreted by means of a five point semi-
quantitative scale. Using this quantification, all but one group I patients
had decreased bone tracer uptake, and all patients of group 3 had an
increased uptake (chi square test of Yates, P <0.001). Among patients
of group 2, bone uptake was decreased in the three patients with clearly
reduced mineralization front and moderate osteitis fibrosa, but it was
increased in all patients with severe osteitis fibrosa and subnormal
mineralization front. A quantitative analysis of regional tracer uptake
into bone was performed in two patients: one of group 2 and one of
group 3. The results obtained clearly corroborated the semi-quantitative
findings, Thus, in hemodialysis patients with symptomatic bone dis-
ease, the 99mTc-MDP bone scan provides useful information for the
differential diagnosis between dialysis—related osteomalacia and sec-
ondary hyperparathyroidism. In patients with mixed lesions, the impor-
tance of bone tracer uptake appears to depend on the extent of the
mineralization front and on the intensity of osteitis fibrosa.
During advanced renal failure histologically diagnosed bone
disease, that is, osteitis fibrosa and/or osteomalacia, is present
in nearly all patients. However, clinical symptoms and signs are
only seen in severe cases. Osteitis fibrosa is due to secondary
hyperparathyroidism [1], osteomalacia is mainly due to vitamin
D deficiency [2, 31 and phosphate depletion [4]. During recent
years the role of aluminum intoxication has been recognized as
an additional important factor in the pathogenesis of osteoma-
lacia in hemodialyzed patients [5—Il].
In these patients the diagnosis of severe hyperparathyroidism
is generally easy and does not require the help of bone biopsy.
'l'he diagnosis of ostcomalacia, by Contrast, is most often only
speculative unless typical Looser—Milkman zones can be ob-
served on x-ray films. Since the presence of these zones is a rare
finding even in severe cases, a bone biopsy must be performed in
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order to establish the diagnosis, at least in all subjects in whom
vitamin D deficiency can be excluded. Furthermore, in patients
with mixed features of both secondary hyperparathyroidism and
osteomalacia, bone histology becomes necessary in order to
evaluate the relative importance of the two lesions.
In this setting the usefulness of procedures less invasive than
bone biopsy, such as isotope bone scan, is controversial since
previous studies using this method have led to conflicting results
[l2—l5].
The purpose of the present study was to re-examine the
usefulness of isotope bone scan in the management and
follow—up of hemodialysis patients with symptomatic bone
disease. The results obtained by 99mTc methylene diphospho-
nate (99mTc-MDP) bone scan were compared to those obtained
by bone histology.
Methods
Patients
The study included 25 uremic patients on intermittent hemo-
dialysis with osteo-articular disease that was symptomatic in 21
of them. They represented the majority of dialysis patients
admitted at our Nephrology Department for renal bone disease
between October 1980 and April 1983. Their main clinical,
biochemical, radiological and histological data are indicated in
Tables 1 and 2. Treatment with vitamin D derivatives had
ceased at least four weeks before investigations. One patient of
group I had undergone parathyroidectomy prior to study.
Three groups of patients were defined according to bone
histology (Table 2). Aluminum (Al)—related bone disease oc-
curred in several patients, and in some patients aplastic oste-
omalacia was observed. In this case matrix synthesis and
mineralization are both severely affected, the number of oste-
oblasts and tetracycline uptake are decreased and osteoidosis
does not develop [16]. For this reason reduced extent of the
mineralization front, rather than widened osteoid seams, was
considered representative of impaired mineralization. The se-
verity of osteitis fibrosa was evaluated by the extent of
trabecular surface covered by osteoclasts and by the presence
of marrow fibrosis.
The three groups were the following: Group I ("osteomala-
cic", patients 1 through 8): reduced extent of the mineralization
front (less than 2 SD below normal, that is, < 54% of osteoid
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Table 1. Clinical data and plasma biochemistry
Patient
Age
years Sex Diagnosi?
Duration
of dialysis
years
Clinical
findings"
Calcium
mmoles/
liter
Phosphorus
mmoles/
liter
Alkaline
phosphatasese
nkat/liter
25(OH)Dd
ng/mliter
iP'FH*
ng/mliter
Aluminum
micromolesi
liter
Group 18
1 66 M CPN 5 + 2.45 3.90 880 73.0 0.56 6.85
2 60 M Unclassified 10 — 2.70 1.40 2050 36.5 1.30 10.00
3 64 M CPN 4 + 2.35 2.48 1240 7.0 1.50 3.40
4 34 F CPN 9 — 2.70 1.05 1400 7.0 0.92 16.50
5 58 M PCD 10 + 2.60 2.00 1160 5.3 0.15 1.60
6 43 F CPN 4 + 2.50 1.85 380 35.0 1.20 7.90
7 48 M Amyloidosis 3 + 2.60 2.60 2230 39.0 0.20 8.05
8 70 M CPN 9 + 2.60 1.95 1135 9.3 0.65 10.80
Mean SD 55.4 6.75 2.56 2.15 1309 26.5 0.81 8.14
±12.5 ±3.01 ±0.12 ±0.87 ±598 ±23.9 ±0.50 ±4.59
Group 2
9 56 M PCD 3 + 2.30 0.90 830 12.0 1.25 10.00
10 61 M CGN 4 + 2.40 1.50 5570 7.1 0.70 21.50
11 62 M CPN 5 + 2.15 2.20 1120 30.0 0.37 2.80
12 35 F CPN 8 — 2.46 0.60 2140 6.0 0.46 5.50
13 30 M CPN 8 — 2.95 1.50 9640 9.0 2.55 3.40
14 60 M PCD 8 + 2.60 1.20 14160 14.0 0.95 6.50
15 69 F Unclassified 2 + 2.70 1.20 7180 3.0 2.05 0.90
Mean ± SD 53.3 5.43 2.5 1.30 5805 11.6 1.19 7.23
± 14.8 ±2.57 ±0.27 ±0.51 ±4942* ±8.9 ±0.83 ±6.94
Group 38
16 56 F CPN 9 + 2.80 1.50 6070 24.0 3.50 3.95
17 48 F CPN 5 + 2.80 1.80 1850 11.0 3.60 3.70
18 58 F PCD 10 + 2.50 1.90 9400 14.0 4.10 6.80
19 66 F PCD 2 + 2.80 1.50 7060 22.0 1.0 3.50
20 59 F PCD 2 + 2.80 1.70 14170 20.0 2.80 6.00
21 31 M Alport's dis. 7 + 2.60 1.20 3020 16.7 2.60 2.55
22 53 F Unclassified 9 + 2.60 2.00 1300 8.5 2.2 0.85
23 60 F Unclassified 5 + 2.85 2.40 8990 10.6 4.20 7.0
24 46 F Unclassified 12 + 2.60 2.0 2140 3.20 4.40 7.80
25 47 M PCD 3 + 2.30 1.65 3800 3.5 1.50 0.90
Mean ± SD 53.3 6.40 2.67 1.77 4780 13.3 2.99 4.31
±10.3 ±3.53 ±0.18 ±0.34 ±2944t ±7.3 ±1.17t0 ±2.50t
a CPN, chronic pyelonephritis; PCD, polycystic kidney disease; CGN, chronic glomerulonephritis.b + is bone pain and/or arthralgia and/or myalgia and/or pruritus.
c Plasma alkaline phosphatases activity (normal range, 500—1500 nkat/liter).d Normal plasma 25 OH D levels are between 5 and 30 nglmliter.
Normal range of plasma iPTH is between 0.1 and 0.5 ng/mliter.
Normal plasma aluminum level, <0.8 smole/liter.
Statistically significant differences (P  0.05) between groups 1 and 2 are indicated by (*), between groups I and 3 by (t), between groups 2
and 3 by (°).
surface), normal osteoclast surface (<1% of trabecular surface)
and absence of significant marrow fibrosis. In this group active
osteoblasts were few or absent. In all these patients Al deposits
were observed at the mineralizing layer of osteoid. Bone tissue
consisted mainly of lamellar bone. Group 2 ("mixed", patients
9 through 15): reduced mineralization front, increased
osteoclast surface (>1% of trabecular surface), presence of
marrow fibrosis; Al deposits were observed in five of seven
subjects; in three patients (patients 13, 14, and 15) osteoblast
surface was greatly increased. Group 3 ("fibrotic", patients 16
through 25): normal extent of the mineralization front (within 2
SD of normal), increased osteoclast surface, significant areas of
marrow fibrosis. Al deposits were observed in seven of ten
patients. These deposits and the great number of osteoblasts are
responsible for the increased osteoid volume and osteoid width
observed in some cases, in spite of normal extent of the
mineralization front. Bone tissue was mainly formed by woven
bone.
Plasma biochemistry
Blood samples were obtained for all patients by puncture of
the arterio-venous fistula immediately before dialysis. Plasma
calcium and phosphorus were measured by Auto Analyzer
SMA 12-60 (Technicon, Domont, France), plasma alkaline
phosphatases according to a kinetic method [17], plasma im-
munoreactive parathyroid hormone [iPTH] by a modification of
the method of Arnaud, Tsao, and Littledike [181 using an
antibody (chicken anti-bovine PTH) that predominantly detects
carboxy-terminal fragments. The iPTH values are expressed as
equivalents of purified bovine P1'H, the lower limit of detection
is 0.1 nglmliter (normal values 0.5 ng/mliter). Plasma 25 OH
vitamin D (25 OH D) concentrations were measured by a compet-
itive protein assay using rat serum as binding protein [19]. Plasma
aluminum was determined by flameless atomic absorption using a
graphite furnace [201.
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Radiology
Osteitis fibrosa lesions included granular rarefaction of the
vault of the skull, subperiosteal erosions of phalanges and
erosions of the distal extremity of clavicule. For osteomalacic
lesions only Looser's zones and pseudo-fractures were consid-
ered as pathognomonic.
Bone histology
Bone biopsies were obtained from the anterior iliac crest. The
samples were embedded in methylmethacrylate. Four rm thick
sections were cut with an A.O. Spencer microtome, equipped
with a knife with tungsten carbide cutting edge, and stained
with toluidine blue (pH 6.4). Morphometrie data were obtained
with Zeiss integrating eyepiece II (Zeiss, Oberkochen, FRG) as
previously reported [9]. The presence of aluminum was dem-
onstrated by the Aluminon method [11]. The amount of alumi-
num was expressed as per cent of the total trabecular surface
and measured at the same magnification as the other histologi-
cal parameters [91. Normal values are those reported by Bordier
et al [211 for the extent of the mineralization front, and those
reported by Schenk, Merz and Muller [22] and by Merz and
Sehenk [23, 24] for all other parameters.
Bone scan
Bone scans were recorded during the days preceding or
following the bone biopsy. Each patient received 15 mCi of
99mTc-methylene diphosphonate (MDP) intravenously. Whole
body scan was performed three hr after the injection using a
Scani Camera (CGR, Paris, France) with two detectors.
Scans were assessed semi-quantitatively in a blinded fashion
by two of us (N.y. and M.F.). Considering normal uptake of the
tracer by bone as zero, the images were scored as follows: —2,
absence of tracer uptake by bone, intense background activity
due to soft tissue uptake; — 1, decrease in bone uptake in the
absence of clear delineation of skeletal structures with intense
soft tissue background; + I, increase in tracer uptake by bone
with sharp delineation of the axial skeleton; +2, marked
Osteoid
Bone vol Osteoid
volume relative surface
93.4
74.6
54.4
84.4
38.7
36.8
36.3
80.4
62.3
23.5
Radiology
Bone Osteitis Osteo-
scan fibrosa malaeia
score (OF) (OM)
5
0
26.7
6.3
20
31.5
25
0
14.3
12.8
81.4
79.8
10
85
62
61.4
52.2
77.6
63.6
24.6
11.6
14.8
5.5
13,7
9.7
11.4
5.7
17.2
11.2
0
0.7
3.6
0.96
0
0
0.6
0
0.7
0.4
0.8
0.78
0.64
0.33
0.5l
0.03
0
0.4
0.3
0
0
0.07
0.43
0
0
0.08
0
0.1
0.2
—2
— 11+2
2
—2
—2
—2
+ +
— +
3.9
62.3
48.7
46.5
63
67.3
63.2
50.7
÷22.0
Patient
Group I
1 23.6 22.6
2 23.5 17.5
3 24.1 6.2
4 26.3 24.5
5 17.1 5.9
6 24.5 5.7
7 31.6 0.24
8 17 19.7
Mean + SD 23.4 12.8
9 17.2 0.3
10 22.4 23.3
11 18.3 3.6
12 30.8 7.13
13 26.1 11.9
14 46.1 9.1
IS 17 10.5
Mean so 25.4
10.4
9.4
Group 3
16 29.2 22.9
17 35.5 11.2
18 24.0 II
19 32.2 7.7
20 21.8 32
21 26.6 6.6
22 22.7 1.4
23 26.8 19
24 24.6 9.42
25 21.6 14.7
Mean SD 26.5 13.5
Normal
values
Mean SD 21 5
÷3
13.9 63.3
36
13
7.8
45
50
5'
51.4
36.3
18.5*
33.8
38.9
62.6
14
0
38
0
26.7
23.1 *
Table 2. Bone histomorphometry data, bone scan score and skeletal x-ray findings
Mean
Mineraliza- Aluminum seam Osteoblast Osteoclast Marrow
tion front surface thickness surface surface fibrosis
_____ - ______ __
Symbols are: statistically significant differences (P = 0.05 or less) between groups I and 2 (1. between groups land 3 by (t) and between groups
2 and 3 by (°). Student's i-test. A significant difference in bone scan scores was found between groups I and 3: Pc 0.001, chi—square test of Yates.
2.9
25.5
5.2
12.4
9.4
11.4
8.6
10.7
0
1.2
2.9
3.36
43.5
37.4
28.7
16.7
19.0*
1.83
1.3
2
1.64
7.4
5.2
8.55
3.9
÷3*
—2
2
4-2
+2
+2
-i2
0.05
0.24
0.09
0.04
8.5
2.7
5.31
2.4
÷33*
+
+
59.4
68.2
61.8
45.6
87
53.4
17,3
64.8
Mi
69.7
59.1
18.2
61.9
68.4
55
75.2
68.9
60
66.9
60
74
64.9
65.5
12
16
48.7
0
36.4
3.8
0
26.7
40
0
18.36
14t
20.2
12
14.6
10.9
17
7.8
4.4
'5
11.8
18.8
13.2
4.9
41.86
34.80
29.30
33.65
34.60
27.50
7.80
43.00
17.80
29.00
29.9
10.6t
3.95
9.42
9.65
5.56
3.50
6.03
3.71
7.70
6.60
10.00
6.6
+2
+2
+2
+1
+2
+2
+2
+2
4-2
+2
34.40
7.18
8.69
13.74
64.80
3.56
l.60
24.50
2.93
4.45
16.6
19.9t
+
-1
+
+
+
+
+
+
+
+
0 10 4.7 0.53
0.54
0 0 — —
Fig. 1. Bone scan features typical for dialysis osteomalacia scored —2
(A), a healthy subject scored 0 (8), and severe secondary hyperpara-
thyroidism in a hemodialysis patient scored +2 (C).
increase in tracer uptake by bone with sharp delineation of the
skeleton including upper and lower limbs. Only diffuse increase
can be considered characteristic, focal increase may be due to
pathological fractures or Looser's zones. In patients with
heterogenous patterns of tracer uptake, the images were scored
Figure 1 shows a typical feature of a patient's bone scan
scored —2, (Fig. 1A), of a normal control scored 0 (Fig. lB),
and of a scan scored +2 (Fig. 1C).
In two patients, one of group 2, the other of group 3, kinetic
studies were performed to obtain a quantitative analysis. The
99mTc-MDP uptake was recorded during 30 mm following the
injection on a "SIMIS IlI-Informatele" computer. The large
field detector (gamma Camera Massiot Philips) was placed on
the pelvis with the anterior incidence. Three regions (R) have
been chosen: on the abdominal aorta (RI); on the posterior iliac
crest (R2), and on the external trochanter (R3). Each R has the
same area (4 files x 4 files) for each patient. The recording on
Ri represents the addition of abdominal background activity,
vascular activity in the aorta, and spinal activity. The recording
on R2 represents the addition of abdominal background activ-
ity, and bone activity on the posterior iliac crest which is
approximately at the same distance from the detector as the
spine. Thus, we computed two curves (Fig. 2); 1) the vascular
curve obtained by subtracting activity in Ri from that in R2 at
(4:
4
I t
I
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each time of recording, and 2) the bone activity curve obtained
directly from R3, the detector being close to the trochanteric
region without important soft tissue interposition.
The bone tissue activity curve may be considered as the
evolution of a tracer content in a non-recirculating pooi of
tracer. The ordinate is tracer content of the system q(t), the
tracer content at steady state is q. This steady—state value is
maintained during a short time after infusion. It then decreases
in an exponential manner. Under this condition, the mean
transit time can be obtained by the value of q(t) at the plateau,
that is, q, divided by the initial slope [34]:
= q (Fig. 2)(dq/dt)t 0
In order to apply this to hemodialyzed patients without exceed-
ing a record time of 30 mm, we have extrapolated the mean
value of q(t) in the last minutes, that is, at about 30 mm, thus
obtaining an estimation of the plateau q. The initial slope of
curve was calculated by linear extrapolation from t = 0 to the
maximum of the vascular curve (tma,j. This slope was normal-
ized by the value q and expressed as mm — One can also
consider the second slope as an approach of the rate of tracer
uptake in bone after the first vascular phase. This second slope
was calculated by extrapolation from tmax to t = 20 nun. The
two curves were presented after three smoothings (9 points).
Calculations have been made before smoothing (Fig. 3).
Statistical analysis of results. Statistical analysis was done
using the chi—square test of Yates or Student's t-test when
appropriate.
Results
Plasma biochemistry
Plasma aluminum concentration was significantly higher in
group I than in group 3 patients (P < 0.02) but not different
between group 2 and group 3 patients. Mean levels of plasma
alkaline phosphatase activities were significantly decreased in
group I patients as compared to group 2 and to group 3 patients.
Mean plasma iPTH concentrations were significantly lower in
group I than in group 3 patients, and also in group 2 than in
1 15 20 101O
Time, mm
Fig. 3. Quantitative analysis of 99mTc-MDP uptake for one osreoma-
lacic dialysis patient (left) and one hyperparathyroid dialysis patient
(right). The full line represents vascular appearance and disappearance
of tracer. The dotted line represents bone uptake of tracer. Bone uptake
of tracer and its vascular disappearance reached an identical activity at
17.2 mm in the osteomalacic patient and at 2.3 mm in the hyperpara-
thyroid patient.
group 3 patients. Mean plasma calcium, phosphorus and 25 OH
D concentrations were similar in patients of all groups (Table 1).
Radiology
Two out of the eight osteomalacic patients of group I presented
typical x-ray features; all patients of group 3 had evidence of
secondary hyperparathyroidism, and one of them had
pseudofractures of the ribs. Two patients of group 2 had bone
x-ray abnormalities compatible with osteomalacia, and five had
radiological evidence of osteitis fibrosa (Table 2).
Bone scan
The results of bone scans are indicated in Table 2. Tracer
uptake by bone was decreased in seven out of eight patients of
group 1, and it was increased in all patients of group 3. Among
the seven patients of group 2, three were scored —1 to —2.
These subjects (patients 9, 10, and 11) had clearly reduced
mineralization front and limited lesions of osteitis fibrosa, that
is, osteoclast surface was increased to 1% to 2% of trabecular
surface, and osteoblast surface was in the normal range. The
remaining four subjects of this group (patients 12 through 15)
were scored + 2, and their mineralization front was only slightly
reduced (> 45% of osteoid surface). In three cases (patients 13,
14, and 15) osteoclast but also osteoblast surfaces were greatly
increased.
Two patients, one of group 2 (patient 11) and one of group 3
(patient 18), were followed during almost two years. Patient 11
had severe Al—related osteomalacia and was scored —1 (Table
2). Al intoxication was stopped by improving dialysis water
treatment and ceasing oral Al intake, and a second bone scan
was performed eight months later which was scored 0 to + 1.
On the second bone biopsy, the extent of the mineralization
front was increased as compared to the first biopsy, from 7.8%
to 35% of osteoid surface, and osteoblasts and osteoclasts were
also increased (from 2% to 5.7%, and from 2.9% to 14,6% of
trabecular surfaces, respectively) indicating the development of
osteitis fibrosa. Indeed, plasma iPTH concentrations had risen
from 0.37 to 1.30 ng/mliter. Patient 18 had secondary hyper-
parathyroidism and was scored + 2 (Table 2). She developed
q(t)
q
dq(t)
— qc
dt t
Slope
1534
1150
767
383
cpm cpm
1118
tmax
Fig. 2. Theoretical representation of the bone activity curve considered
as the evolution of a tracer content in a non-recirculating system [24/.
The circulating pool of tracer provides a constant rate infusion.
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Table 3. Kinetic study results of tracer uptake on patients 11 and 18
q,b
cpm
(dq(t)\
t =
cpm mm -
-
—
q(\
\ dt )t = 01
mm
_)\ t = 20 mm
dt ) I = tma
cpm mm -
Osteomalaciaa 300 61.5 4.88 10.2
(tmax = 3 sec)
Hyperparathyroidism 550 271.2 2.04 13.2(t,,ax = 1.25 sec)
a Maximum of the vascular curve.
b Bone tracer content at steady state.
Initial slope of bone activity curve.d Mean transit time.
Second slope of bone activity curve.
osteomalacia within eighteen months after parathyroidectomy.
On the bone biopsy, the extent of the mineralization front
decreased from 55% to 0%, osteoblasts decreased from 29.3%
to 0.7%, and osteoclasts from 9.65% to 1.53% of trabecular
surface. At that time the tracer uptake had decreased from + 2
to —1.
The results of the kinetic studies of tracer uptake performed
in patient 11 (group 2) and in patient 18 (group 3) are repre-
sented in Table 3. Patient 11 had prevailing osteomalacic
lesions, and patient 18 severe osteitis fibrosa. Thirty mm after
the injection the skeletal uptake of 99mTc-MDP was 8.5% of the
administered dose in patient 11, and 47% in patient 18. The
bone uptake of tracer and its disappearance from blood vessels
reached an identical activity at 17.2 mm in the osteomalacic
patient, and at 2.3 mm in the hyperparathyroid patient. Table 3
shows that bone tracer content at steady—state and initial bone
activity slope were markedly lower and more flattened, respec-
tively, in the osteomalacic patient as compared to the hyper-
parathyroid patient. In line with this, the mean transit time was
longer in the former as compared to the latter.
Discussion
The present study shows that in hemodialysis patients with
symptomatic bone disease, results of 99mTc-MDP bone scan
are closely related to those of bone histology. Tracer uptake
was decreased in all patients with pure osteomalacia, in whom
low mineralization front and absence of osteitis fibrosa were
observed on bone biopsies, and it was increased in all patients
with pure osteitis fibrosa who had numerous osteoclasts and
osteoblasts, and normal mineralization front. Among the pa-
tients with mixed lesions, tracer uptake was low in those with
clearly reduced mineralization front and moderate osteitis
fibrosa, and it was increased in those patients in whom second-
ary hyperparathyroidism induced an increase not only of oste-
oclasts but also of osteoblasts, although mineralization front
was not completely normal.
Among the patients with pure osteomalacia heterogeneous
tracer bone uptake occurred in one case (patient 4), This could
be explained by the existence of a spina bifida which may have
changed the rate of diffusion of the tracer to the axial skeleton.
Tracer uptake by bone depends on the bone blood flow [25],
on the affinity of the ligand for the bone tissue, and on the
affinity of bone tissue for the ligand, that is, diphosphonates.
The mechanism of skeletal uptake of these substances is not
clearly understood. Disphosphonates are synthetic compounds
related in structure with the pyrophosphates found in biological
fluids and in mineralized tissues [26]. Their behavior in vitro
closely resembles those of pyrophosphates: they bind on the
surface of bone mineral [26] and their affinity for amorphous
calcium phosphate is greater than for crystalline hydroxyapatite
[27]. This may explain our observation that tracer uptake is
related to the extent of the mineralization front, since this site of
active mineral deposition is characterized by the presence of
amorphous calcium phosphate whereas hydroxyapatite crystals
arise later, as the bone becomes more mature [28]. Moreover
the woven bone observed in patients with secondary hyperpara-
thyroidism may have contributed to increased tracer uptake.
Woven bone contains collagen fibers which are deposited in an
irregular, disordered pattern. This bone mineralizes in a manner
considerably different from adult lamellar bone [29] and con-
tains probably increased amounts of amorphous calcium phos-
phate [30]. For these reasons it is likely that the amount of
amorphous phosphate present in the bone of patients with
osteitis fibrosa is greater than in those with osteomalacia.
In the patient groups studied, osteomalacia due to vitamin D
deficiency was not observed. Plasma 25-OH-D concentrations
were in the normal range in all but three subjects (patients 15,
24, and 25); mineralization front was normal in two of these
patients, and only slightly decreased in the third. Impaired
mineralization was mainly related to Al intoxication since Al
deposits were present in 13 out of 15 patients with reduced
mineralization front. The high Al concentration, the relatively
low IPTH concentrations and the normal or only slightly increased
alkaline phosphatase activities observed in the plasma of these
patients further point to the toxic origin of their bone disease,
since such a plasma biochemistry constellation is characteristic of
dialysis osteomalacia [9, 16]. Al could possibly have directly
inhibited the adsorption of MDP on bone mineral, but the pres-
ence of Al deposits in several patients with elevated tracer uptake
is against this hypothesis.
Besides the role played by the crystallinity of bone mineral,
cellular activity appears also to be related with MDP adsorp-
tion. In all patients but one with increased bone tracer uptake,
osteoclast surface and osteoblast surface were also increased.
The role of the cellular activity is clearly shown by patient 11 in
whom reduced tracer uptake related to Al osteopathy was
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found increased eight months after the intoxication had ceased.
At that time, mineralization front had increased but was still
low whereas osteoblasts and osteoclasts had increased to three
times the normal value.
These results are in agreement with those reported by
Kessler et al [14] who found using MDP that bone scans provide
information which is not visualized radiologically. Vanher-
weghem et al [15] using 99mTc-pyrophosphate (99mTc-PP)
have shown that tracer uptake by bone correlates with bone
calcium accretion rate. For these authors 99mTc-PP bone scan
may detect acquired impairment of bone mineralization related
to Al intoxication. Botella et al [31] reviewed bone scans of
patients with dialysis osteomalacia after desferrioxamine ther-
apy. Bone tracer deposits were lacking before treatment, and
had reverted to normal or to a pattern typical of secondary
hyperparathyroidism after the symptoms of Al intoxication had
disappeared. However, these authors did not perform concom-
itant bone biopsy and thus had to rely for comparison on more
indirect parameters such as clinical, biochemical, and x-ray
data. However, the latter are insufficient for the diagnosis of
dialysis osteomalacia in many cases. This is clearly shown by
the results of the present study where plasma iPTH concentra-
tions were markedly elevated (> 1.2 ng/mliter) in three patients,
and plasma alkaline phosphatase activities in two, whereas
bone scan indicated osteomalacia which was confirmed by bone
biopsy. It is noteworthy that the PTH radioimmunoassay used
in our study detected mainly the inactive C-terminal fragments
of the hormone. At the time that this study was performed the
desferrioxamine test [321 was not yet routinely used. This test is
able to measure total body Al burden. In our recent experience,
the result of this test does however not exactly predict the
severity and the type of the bone lesion in hemodialysis
patients.
In contrast to the above bone scan studies [14, 15] and to our
results, Hodson et al [121 comparing bone scans and bone
histology came to the conclusion that bone scans do not provide
useful information on the type and severity of renal osteodys-
trophy. However, the histological parameters used for compar-
ison are osteoid area and osteoid-osteoclast index which both
may be increased in osteomalacia as well as in osteitis fibrosa.
Moreover, osteoblast surface was not analyzed, and this pa-
rameter appears to be more closely related to serum PTH than
osteoclast count [33].
The semi-quantitative evaluation of bone scans was con-
firmed by the kinetic studies performed in two patients, which
showed that the tracer activity measured in bone 30 mm after
the injection of 99mTc-MDP was six times greater in fibrotic
than in osteomalacic bone. These results are in line with those
obtained by Cochran and Stephens [34] in hemodialysis patients
using an expanding pool model of radiocalcium kinetics.
In conclusion, the present study suggests that in hemodialysis
patients with symptomatic bone disease, 99mTc-MDP bone
scan constitutes a valuable, non-invasive method of explora-
tion. Its predictive value for either osteitis fibrosa or impaired
mineralization due to Al toxicity is reliable when compared to
histomorphometric data, Biochemical parameters such as plasma
iPTH and aluminum may be misleading. Measurement of the
former using C-terminal antibodies often cannot distinguish be-
tween active and inactive circulating fragments of the hormone.
The latter does not generally reflect the type of bone lesion. Serum
alkaline phosphatases combined with radiological findings are
most often helpful in establishing the diagnosis of osteitis fibrosa
but not that of osteomalacia. However, in the absence of bone
biopsy, the introduction of the 99mTc-MDP bone scan as a new
diagnostic method allows to establish the diagnosis of the precise
type of bone lesion more accurately.
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